Turkey: Healthcare

Turkey's pharmaceutical pricing system undergoes significant transformation with new regulations introducing a 65% Euro/TL conversion rate, incentive mechanisms for first generic products, and the groundbreaking introduction of value-based pricing concepts. The new framework aims to accelerate generic market entry while addressing long-standing challenges in patient access to innovative treatments.

Turkey's pharmaceutical pricing system undergoes a major restructuring with the publication of the New Pricing Communiqué on August 29, 2026, implementing significant changes including increased Euro/TRY conversion rates, incentive mechanisms for first generic market entry, and the introduction of value-based pricing concepts. The new regulations establish detailed provisions for special product categories while leaving certain implementation details to future secondary legislation.

Turkey has become a major destination for medical tourism, but when treatment goes wrong abroad, patients often don't know their legal rights. This guide examines the regulatory framework governing health tourism in Turkey, common causes of medical malpractice in cosmetic and dental procedures, and the practical steps foreign patients can take to pursue compensation claims under Turkish law.

Bu çalışmada, sağlık meslek mensuplarına ve sağlık kurum ve kuruluşlarına yapılan değer aktarımlarının Türkiye’deki hukuki çerçevesi incelenmektedir. Sağlık sektöründe farklı paydaşlar arasında yürütülen bilimsel iş bir likleri, eğitim faaliyetleri ve tanıtım faaliyetleri kapsamında sağlık meslek mensuplarına çeşitli finansal veya ayni destekler sağlanabilmektedir. Bu tür ilişkilerin şeffaflık, etik kurallar ve kamu sağlığı ilkeleri çerçevesinde yürütül mesi, sağlık hizmetlerinin tarafsızlığının korunması ve toplumun sağlık sistemine duyduğu güvenin sürdürülmesi açısından büyük önem taşımaktadır.

Emergency departments operate under intense pressure, where rapid decisions can mean the difference between recovery and permanent harm. While not every adverse outcome constitutes negligence, certain failures to meet accepted medical standards in emergency settings may result in serious consequences for patients and potential grounds for legal action.

Turkey's Ministry of Health has introduced significant amendments to the Personal Health Data Regulation, fundamentally changing how individuals can request re-evaluation of previously diagnosed medical conditions.

Turkey's healthcare system underwent significant reforms in July 2025 with the adoption of Law No. 7557, introducing comprehensive updates to modernize services, enhance efficiency, and strengthen oversight mechanisms. These changes bring critical implications for life sciences companies operating in Turkey, particularly regarding physician practice limitations, advertising restrictions, pharmaceutical tracking systems, and digital consent frameworks.

Turkey's alternative reimbursement models enable innovative pharmaceuticals to be covered outside standard pricing rules, allowing the Social Security Institution to negotiate discount rates and budget caps. A new initiative launching in January 2027 will systematically produce real-world clinical data and pharmacoeconomic evaluations for named patient program products to strengthen evidence-based reimbursement decisions.

Life sciences companies in Turkey navigate a complex regulatory framework governing interactions with healthcare professionals, where promotional activities face strict oversight and compliance expectations continue to intensify. While pharmaceutical promotion remains limited to healthcare professionals with mandatory transparency reporting, medical device regulations show signs of convergence in enforcement practices.